Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease | Journal of Neuroinflammation BioMed Central Research Open Access Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson s disease Rosario Sanchez-Pernaute1 2 Andrew Ferree1 2 Oliver Cooper1 2 Meixiang Yu1 3 Anna-Liisa Brownell1 3 and Ole Isacson 1 2 Address 1McLean Hospital Harvard University Udall Parkinson s Disease Research Center of Excellence Belmont Massachusetts USA 2Neuroregeneration Laboratories McLean Hospital Belmont Massachusetts USA and 3Department of Radiology Massachusetts General Hospital Boston Massachusetts USA Email Rosario Sanchez-Pernaute - rosario_pernaute@hms.harvard.edu Andrew Ferree - aferree@mclean.harvard.edu Oliver Cooper - ocooper@mclean.harvard.edu Meixiang Yu - ymeixiang@partners.org Anna-Liisa Brownell - abrownell@partners.org Ole Isacson - isacson@hms.harvard.edu Corresponding author Published 17 May 2004 Received 01 April 2004 Journal of Neuroinflammation 2004 1 6 Accepted 17 May 2004 This article is available from http www.jneuroinflammation.eom content 1 1 6 2004 Sanchez-Pernaute et al licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Several lines of evidence point to a significant role of neuroinflammation in Parkinson s disease PD and other neurodegenerative disorders. In the present study we examined the protective effect of celecoxib a selective inhibitor of the inducible form of cyclooxygenase COX-2 on dopamine DA cell loss in a rat model of PD. We used the intrastriatal administration of 6-hydroxydopamine 6-OHDA that induces a retrograde neuronal damage and death which progresses over weeks. Animals were randomized to receive celecoxib 20 mg kg day or vehicle starting 1 hour before the intrastriatal administration of 6-OHDA. Evaluation was performed in vivo using micro PET and selective .
